EE317 Cost-Effectiveness of Adjuvant Olaparib in Germline BRCA1/2-Mutated, High-Risk, Human Epidermal Growth Factor-2-Negative Early Breast Cancer: A Canadian Perspective
Abstract
Authors
A Parackal E Ting A Verhoek A Joy S Sehdev R Hettle